Table 2 Descriptive statistics of the SMs in DTC survivors by their treatment
Number of patients, n(%) | Number of Females, n(%) | Proportion of patients by race(W/B/API) | Proportion of patients by disease stage (Local/Regional/Distant) | Median age at diagnosis of the SMs, yrs | Median follow-up time since the diagnosis of SMs,months | Median latency time, months | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
+RAI | -RAI | +RAI | -RAI | +RAI | -RAI | +RAI | -RAI | +RAI | -RAI | +RAI | -RAI | +RAI | -RAI | |
All cancer combined | 2289 | 2339 | 68.7% | 72.6% | 83%/5%/11% | 85%/8% /0% | 50%/18% /17% | 50%/21% /16% | 62 | 64 | 28 | 26 | 70 | 70 |
Oral Cavity and Pharynx | 56 | 51 | 64.3% | 64.7% | 79%/5% /16% | 78%/12%/10% | 48%/11% /7% | 39%/12% /8% | 58 | 59 | 22 | 24 | 68 | 73 |
Digestive System | 319 | 356 | 69.0% | 72.5% | 78%/8% /14% | 81%/10%/10% | 36%/28% /24% | 34%/32% /4% | 64 | 65 | 19 | 14 | 73 | 68 |
Respiratory System | 247 | 254 | 68.8% | 72.4% | 82%/5% /12% | 83%/9% /8% | 24%/17% /52% | 24%/24% /48% | 68 | 66 | 14 | 10 | 68 | 66 |
Skin | 138 | 137 | 63.0% | 67.2% | 96%/1% /4% | 96%/1% /2% | 76%/9% /3% | 78%/11% /1% | 56 | 64 | 35 | 31 | 65 | 68 |
Breast | 547 | 574 | 99.5% | 99.8% | 80%/5% /15% | 82%/10%/8% | 65%/30% /4% | 66%/30% /3% | 58 | 61 | 35 | 34 | 73 | 74 |
Female Genital System | 179 | 206 | 100.0% | 100.0% | 83%/7% /10% | 82%/5% /12% | 61%/16% /16% | 51%/23% /21% | 60 | 62 | 29 | 26 | 66 | 67 |
Male Genital System | 237 | 233 | 0.0% | 0.0% | 84%/7% /9% | 88%/9% /3% | 79%/14% /3% | 82%/12% /2% | 65 | 66 | 38 | 50 | 70 | 69 |
Urinary System | 194 | 191 | 43.3% | 57.6% | 89%/3% /8% | 90%/5% /6% | 55%/12% /10% | 56%/9% /8% | 64 | 67 | 30 | 31 | 71 | 78 |
Nervous System | 30 | 36 | 80.0% | 69.4% | 87%/7% /7% | 94%/3% /0% | 73%/20% /3% | 86%/8% /0% | 57 | 60 | 15 | 12 | 55 | 60 |
Hematologic System | 261 | 215 | 65.1% | 65.6% | 84%/4% /11% | 87%/7% /4% | NA | NA | 63 | 66 | 27 | 23 | 65 | 73 |